Equipoise should be amended, not abandoned

Clinical Trials

Volumn 8, Issue 4, 2011, Pages 408-416

  Van Der Graaf, Rieke ^a   Van Delden, Johannes J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; PLACEBO; VEMURAFENIB;

ARTICLE; CLINICAL RESEARCH; COMMUNITY; CONTROLLED CLINICAL TRIAL (TOPIC); EQUIPOISE; ETHICAL DECISION MAKING; HEMOPHILIA; HUMAN; JOINT FUNCTION; KNOWLEDGE; MEDICAL LITERATURE; MELANOMA; METASTASIS; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SEMANTICS; VALIDITY;

DISSENT AND DISPUTES; PROFESSIONAL ROLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPEUTIC EQUIPOISE;

EID: 80051677372     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774511409600     Document Type: Article

References (60)

1. Bruce J. Operable cancer of the breast: a controlled clinical trial. Cancer. 1971 ; 28: 1443-52
2. Shaw LW, Chalmers TC. Ethics in cooperative clinical trials. Ann N Y Acad Sci. 1970 ; 169: 487-95
3. Fried C Medical Experimentation: Personal Integrity and Social Policy. Amsterdam: North-Holland Publishing Company ; 1974 :
4. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987 ; 317: 141-45 (Pubitemid 17092151)
5. Gifford F. Community-equipoise and the ethics of randomized clinical trials. Bioethics. 1995 ; 9: 127-48
6. Kukla R. Resituating the principle of equipoise: justice and access to care in non-ideal conditions. Kennedy Inst Ethics J. 2007 ; 17: 171-202
7. Karlawish JHT, Lantos J. Community equipoise and the architecture of clinical research. Camb Q Healthc Ethics. 1997 ; 6: 385-96 (Pubitemid 127685122)
8. Lilford RJ, Jackson J. Equipoise and the ethics of randomization. J R Soc Med. 1995 ; 88: 552-59
9. Ashcroft R. Equipoise, knowledge and ethics in clinical research and practice. Bioethics. 1999 ; 13: 314-26 (Pubitemid 29364902)
10. Sackett DL. Equipoise, a term whose time (if it ever came) has surely gone. Can Med Assoc J. 2000 ; 163: 835-36
11. Joffe S, Truog R The Oxford Textbook of Clinical Research Ethics. Emanuel , ed. New York: Oxford University Press ; 2008: 245-60.
12. Miller PB, Weijer C. Rehabilitating equipoise. Kennedy Inst Ethics J. 2003 ; 13: 93-118 (Pubitemid 37130489)
13. Miller PB, Weijer C. Equipoise and the duty of care in clinical research: a philosophical response to our critics. J Med Philos. 2007 ; 32: 117-33 (Pubitemid 46598158)
14. Miller PB, Weijer C. Revisiting equipoise: a response to Gifford. Kennedy Inst Ethics J. 2007 ; 17: 227-46
15. Miller FG, Brody H. What makes placebo-controlled trials unethical. Am J Bioeth. 2002 ; 2: 3-9
16. Miller FG, Brody H. A critique of clinical equipoise: therapeutic misconception in the ethics of clinical trials. Hastings Cent Rep. 2003 ; 33: 19-28
17. Brody H, Miller FG. The clinical investigator: unavoidable but manageable tension. Kennedy Inst Ethics J. 2003 ; 13: 329-46 (Pubitemid 38178106)
18. Miller FG, Brody H. Clinical equipoise and the incoherence of research ethics. J Med Philos. 2007 ; 32: 151-65 (Pubitemid 46598162)
19. Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med. 2011 ; 364: 476-80
20. Gifford F. Pulling the plug on clinical equipoise: a critique of Miller and Weijer. Kennedy Inst Ethics J. 2007 ; 17: 203-26
21. London AJ The Oxford handbook of bioethics. Steinbock B, ed. Oxford: Oxford University Press ; 2007a: 571-96.
22. Chiong W. The real problem with equipoise. Am J Bioeth. 2006 ; 6: 37-47 (Pubitemid 44181297)
23. Shamoo AE. The myth of equipoise in phase I clinical trials. Medscape J Med. 2008 ; 10: 254-254
24. Marquis D. Leaving therapy to chance. Hastings Cent Rep. 1983 ; 13: 40-47
25. London AJ. Two dogmas of research ethics and the integrative approach to human-subjects research. J Med Philos. 2007b ; 32: 99-116 (Pubitemid 46598163)
26. Gifford F. Freedman's clinical equipoise and sliding-scale all-dimensions-considered equipoise. J Med Philos. 2000 ; 25: 399-426
27. Gifford F. So-called clinical equipoise and the argument from design. J Med Philos. 2007 ; 32: 135-50 (Pubitemid 46598159)
28. Weijer C, Miller PB. Therapeutic obligation in clinical research. Hastings Cent Rep. 2003 ; 33: 3-3
29. Miller PB, Weijer C. Fiduciary obligation in clinical research. J Law Med Ethics. 2006 ; 34: 424-40 (Pubitemid 43936932)
30. Weijer C, Miller PB. When are research risks reasonable in relation to anticipated benefits. Nat Med. 2004 ; 10: 570-73 (Pubitemid 38796840)
31. Weijer C. The ethical analysis of risks and potential benefits in human subjects research: history, theory, and implications for US regulation, in ethical and policy issues in research involving human participants. 2001 Volume II - Commissioned papers and staff analysis, National Bioethics Advisory Commission (NBAC). Bethesda MD: NBAC, P1-P29.
32. Van der Graaf R, Van Delden JJM. What is the best standard for the standard of care in clinical research. Am J Bioeth. 2009 ; 9: 35-43
33. London AJ. Equipoise and international human-subjects research. Bioethics. 2001 ; 15: 312-32 (Pubitemid 32734181)
34. Freedman B. Placebo-controlled trials and the logic of clinical purpose. IRB: A Rev Hum Subj Res. 1990 ; 12: 1-6
35. Rid A, Wendler D. Risk-benefit assessment in medical research-critical review and open questions. Law, Probab Risk. 2010 ; 9: 151-77
36. Litton P, Miller FG. What physician-investigators owe patients who participate in research. JAMA. 2010 ; 304: 1491-92
37. Wertheimer A Widening the Lens: Rethinking the Ethics of Clinical Research. Oxford: Oxford University Press ; 2010 :
38. Anderson JA. Contextualizing clinical research; the epistemological role of clinical equipoise. Theor Med Bioeth. 2009 ; 30: 269-88
39. Lilford RJ. Equipoise is not synonymous with uncertainty. BMJ. 2001 ; 323: 574-75
40. Veatch RM. Indifference of subjects: an alternative to equipoise in randomized clinical trials. Soc Philos Policy. 2002 ; 19: 295-323
41. Veatch RM. The irrelevance of equipoise. J Med Philos. 2007 ; 32: 167-83 (Pubitemid 46598164)
42. Livingstone E, Zimmer L, Piel S, Schadendorf D. PLX4032: does it keep its promise for metastatic melanoma treatment. Expert Opin Investig Drugs. 2010 ; 19: 1439-49
43. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical. JAMA. 2000 ; 283: 2701-11 (Pubitemid 30337334)
44. Beauchamp TL, Childress JL Principles of Biomedical Ethics. New York, Oxford: Oxford University Press ; 2009 :
45. Richardson HS. Specifying, balancing and interpreting bioethical principles. J Med Philos. 2000 ; 25: 285-307 (Pubitemid 30418969)
46. Chabner, Bruce A. Early accelerated approval for highly targeted cancer drugs. N Engl J Med. 2011 ; 364: 1087-89
47. National Hemophilia Foundation. MASAC recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding) [Medical Bulletin #193.Chapter Advisory 197], Available at: www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid = 57&contentid = 1007 (accessed on 11-3-1994).
48. Medical and Scientific Advisory Council (MASAC) Recommendation 2001 #117 concerning prophylaxis. Prophylactic administration of clotting factor concentrate to prevent bleeding. http://www.hemophilia.org/NHFWeb/MainPgs/ MainNHF.aspx?menuid=51&contentid=296.
49. Nilsson IM, Blomback M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia. Bibl Haematol. 1970 ; 34: 111-24
50. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992 ; 232: 25-32
51. Aronstam A, Arblaster PG, Rainsford SG, et al. Prophylaxis in haemophilia: a double-blind controlled trial. BMJ. 1976 ; 33: 81-90
52. Schimpf K, Fischer B, Rothmann P. Die ambulante dauerbehandlung der hämophilie A. Dtsch Med Wochenschr. 1976 ; 101: 141-48
53. Berntorp E, Astermark J, Bjorkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia. 2003 ; 9: 1-4 (Pubitemid 36622042)
54. Stobart K, Irio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B (Review). Cochrane Database Syt Rev. 2005 ;: 2-2
55. Manco-Johnson MJ, et al. Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency. Blood. 2005 ; 106: Abstract 3 - Abstract 3
56. Aledort L, Ljung R, Blanchette V. Are randomized clinical trials the only truth? Not always. J Thromb Haemost. 2006 ; 4: 503-4
57. Mannucci PM. Need for randomized trials in hemophilia. J Thromb Haemost. 2006 ; 4: 501-02
58. More on: are randomized clinical trials the only truth? Not always. J Thromb Haemost. 2006 ; 4: 1167-68
59. White GC. Parachutes and prophylaxis: they both work!. J Thromb Haemost. 2006 ; 4: 1226-7
60. Fischer K, Grobbee DE, Van den Berg HM. RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia. Haemophilia. 2007 ; 13: 345-50 (Pubitemid 47040161)